GeneBioTech KRX:086060KOSDAQ
진바이오텍 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days2
Articles tracked0since Sep 11
In Q2 2026, GeneBioTech reported revenue of ₩23.0bn, down 0.5% year on year, and operating profit of ₩1.5bn. GeneBioTech (진바이오텍) appeared in 0 Korean news articles and 2 DART filings over the past seven days.
Filing signals New 5% holder Major holder adding Screener
GeneBioTech quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩23.0bn | -0.5% | ₩1.5bn margin 6.5% | ₩1.3bn |
| Q1 2026 | ₩21.5bn | -5.9% | ₩763m margin 3.6% | ₩565m |
| Q4 2025 derived | ₩20.5bn | -6.8% | ₩916m margin 4.5% | ₩829m |
| Q3 2025 | ₩24.3bn | +18.7% | ₩1.4bn margin 5.6% | ₩986m |
| Q2 2025 | ₩23.1bn | +13.8% | ₩897m margin 3.9% | ₩1.2bn |
| Q1 2025 | ₩22.8bn | +13.4% | ₩749m margin 3.3% | ₩765m |
| Q4 2024 derived | ₩22.0bn | +12.6% | ₩1.3bn margin 5.9% | ₩722m |
| Q3 2024 | ₩20.4bn | +2.4% | ₩699m margin 3.4% | ₩903m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
GeneBioTech top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest GeneBioTech news Korean headlines
No articles yet.